Drugs / CLDN6 modRNA-LPX
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04503278 | Sep 2020 → Aug 2028 expected | cancer | BioNTech Cell & Gene Therapies GmbH | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CLDN6 modRNA-LPX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04503278 ↗ |
| Route | Intravenous | “administered as an i.v. injection at protocol-specified intervals.” NCT04503278 ↗ |